Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 54Breast Neoplasms 37Fallopian Tube Neoplasms 22Multiple Myeloma 19Carcinoma, Ovarian Epithelial 15Neoplasms 12Lymphoma 10Triple Negative Breast Neoplasms 7Neoplasm Metastasis 6Lymphoma, Large B-Cell, Diffuse 6Recurrence 5Hodgkin Disease 4Breast Neoplasms, Male 4Solid Tumors 3Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Anaplastic 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Sarcoma 2Peritoneal Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2

Interventions

Paclitaxel 18Carboplatin 16Taxes 12Cisplatin 7Bevacizumab 7Immunoglobulin G 4Disulfides 4Topotecan 3VTX-2337 2SS1(dsFv)PE38 2Platinum 2Filgrastim 2Erlotinib Hydrochloride 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1trioctyl phosphine oxide 1sargramostim 1pegfilgrastim 1paclitaxel poliglumex 1liposomal doxorubicin 1elesclomol 1belinostat 1Thiotepa 1Reverse Transcriptase Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Mental Status and Dementia Tests 1Melphalan 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Brenner Tumor × liposomal doxorubicin × Clear all
NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡